Heart attack drug shows promise in reducing damage
NCT ID NCT06187727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a medicine called henagliflozin can reduce the size of heart damage and improve heart function in people who had a severe heart attack. 248 adults took the drug or a placebo for 6 months after a procedure to open blocked arteries. Researchers measured heart enzyme levels and checked for future heart problems to see if the drug helps recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA general hospital
Beijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict how well the heart heals after an attack?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Could a hot bath after exercise help heal the heart?
- Can a Plant-Based diet calm the immune system after a heart attack?
- Poles apart? nordic walking may outpace standard rehab for heart failure